Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.

about

Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.

Item

http://www.wikidata.org/entity/Q43596419

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Long-term molecular remission ...... chronic lymphocytic leukemia.

@en

Long-term molecular remission ...... chronic lymphocytic leukemia.

@nl

type

Item

label

Long-term molecular remission ...... chronic lymphocytic leukemia.

@en

Long-term molecular remission ...... chronic lymphocytic leukemia.

@nl

prefLabel

Long-term molecular remission ...... chronic lymphocytic leukemia.

@en

Long-term molecular remission ...... chronic lymphocytic leukemia.

@nl

P1476

Long-term molecular remission ...... chronic lymphocytic leukemia.

@en

P2093

Francesca Rezzonico

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Immune reconstitution in chronic lymphocytic leukemia

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

Flow cytometry and polymerase chain reaction-based analyses of minimal residual disease in chronic lymphocytic leukemia.

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia

Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.

Lenalidomide for the treatment of B-cell malignancies.

Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation.

P304

340-344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/EJH.12068

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lucia Farina

Paolo Corradini

Francesco Spina

P577

2013-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23281656

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte